SBI 101 - Sentien Biotechnologies

Drug Profile

SBI 101 - Sentien Biotechnologies

Alternative Names: SBI-101

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sentien Biotechnologies
  • Class Stem cell factors
  • Mechanism of Action Immunosuppressants; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute kidney injury

Most Recent Events

  • 01 May 2017 Phase-I/II clinical trials in Acute kidney injury (In adults, In the elderly) in USA (Parenteral) (NCT03015623)
  • 02 Nov 2016 Sentien Biotechnologies intends to file an IND application with the US FDA for Acute Kidney Injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top